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As bacteria continue to gain 
resistance to a broader spectrum of  
antibiotics, it is imperative that scientists 
design and synthesize novel antibiotics 
in order to combat the growing problem 
with resistance. There are many different 
ways to kill bacteria, one of  them being 
to prevent bacteria from synthesizing 
proteins. Just like humans, all bacteria 
have DNA that contains their genetic 
information. This information is used by 
the bacteria to make the proteins they 
need to survive. The process of  protein 
synthesis, known as the Central Dogma 
of  Microbiology, involves transcription, 
translation and translocation; each step 
of  this process has been the target of  
different antibiotics. 
Recently, the antibiotic Linezolid has 
been proven effective in treating antibiotic 
resistant bacteria such as methicillin-
resistant Staphylococcus aureus (MRSA), 
multidrug-resistant Mycobacterium 
tuberculosis (MDR-TB) and vancomycin-
resistant Enterococcus spp. (VRE). 
Linezolid belongs to a class of  antibiotics 
known as Oxazolidinones, and it 
prevents protein synthesis by stopping the 
translation of  mRNA into protein. This 
translation process is mediated by the 
bacterial ribosome, which is the target of  
Linezolid. The bacterial ribosome is made 
up of  two subunits: the large (50s) subunit 
and the small (30s) subunit. The bacterial 
ribosome is distinctly different from that 
of  a humans allowing species specificity. 
Linezolid binds to the peptidyltransferase 
center (PTC) of  the 50s ribosomal 
subunit and halts protein synthesis. 
Without the proteins necessary to regulate 
processes within the cell, the bacteria 
dies. Unfortunately, approximately 1 year 
after its initial use, some bacteria have 
presented with resistance to Linezolid. 
The design and synthesis of  
novel analogues of  Linezolid with an 
increased binding affinity may combat 
bacterial resistance to Linezolid. The 
structure of  Linezolid bound to its 
target indicates there was only one key 
hydrogen bond between its morpholine 
ring and a neighboring uracil group on 
the ribosome. We hypothesize that we 
can increase the binding affinity of  our 
analogues by increasing the number of  
potential hydrogen bonding sites that 
can interact with the key uracil group 
or surrounding bases. The goal of  this 
project is to incorporate cyclic dipeptides 
to introduce the necessary functionality. 
The synthesis was designed to 
utilize a core intermediate allowing for 
functionalization at each end. Initially, 
the construction of  this core intermediate 
was investigated. Several attempts 
to form the key oxazolidinone were 
performed; however, this process needs 
to be optimized. A model system was 
used to evaluate the coupling reaction 
to attach the required cyclic dipeptide. 
The coupling of  glycine anhydride was 
successful utilizing a copper (II) catalyst, 
but this reaction needs to be optimized. 
 After investigating the oxazoldinone 
ring formation and copper coupling 
reactions, biological tests will be 
performed in hopes that the novel 
derivatives of  Linezolid will present with 
antibacterial activity. Further studies will 
indicate whether these derivatives can be 
used to treat drug resistant bacteria.
